Canadian Online Pharmacy

Drug Information Update - FDA issues alert about lack of sterility assurance of drug products from ApotheCure, Inc. and NuVision Pharmacy and of forthcoming recall

FDA Division of Drug Information: Know the Moment It Happens

The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.


The U.S. Food and Drug Administration is alerting health care providers, hospital supply managers, and pharmacists that sterile drug products made by ApotheCure, Inc. and sterile lyophilized (freeze dried powder) drug products made by NuVision Pharmacy were produced under conditions that could create a high potential for contamination. These products should not be administered to patients.

Sterile drug products that are contaminated place patients at risk of serious infection. The FDA advises health care providers and hospital staff to immediately check their medical supplies and quarantine any sterile products from ApotheCure, Inc. or sterile lyophilized products from NuVision Pharmacy.

ApotheCure, Inc. and NuVision Pharmacy have informed the FDA that they have initiated a voluntarily recall of all sterile products made and distributed by ApotheCure, Inc. and all sterile lyophilized products made and distributed by NuVision Pharmacy. Facilities and health care providers who have received the affected products should keep them quarantined until ApotheCure Inc. and NuVision Pharmacy issue public notification and communicate further instructions to purchasers on what to do with the products. Patients who were administered any sterile drug products produced and distributed by ApotheCure, Inc. and any sterile lyophilized product distributed by NuVision Pharmacy and have concerns should contact their health care providers.

For more information, please visit: ApotheCure/NuVision


 

This is an automated message delivery system.  Replying to this message will not reach DDI staff.  If you have comments or questions, please contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from 8:00 am - 4:30 pm Monday - Friday.  You can also email us at druginfo@fda.hhs.gov.

 


This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 Powered by GovDelivery